Lexeo Therapeutics, Inc. (LXEO)
4.07
-0.13
(-3.10%)
USD |
NASDAQ |
Sep 21, 16:00
4.07
0.00 (0.00%)
After-Hours: 20:00
Lexeo Therapeutics Enterprise Value : 125.32M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 125.32M |
| September 17, 2026 | 123.75M |
| September 16, 2026 | 122.18M |
| September 15, 2026 | 119.82M |
| September 14, 2026 | 126.11M |
| September 11, 2026 | 129.25M |
| September 10, 2026 | 137.90M |
| September 09, 2026 | 147.34M |
| September 08, 2026 | 169.35M |
| September 04, 2026 | 179.57M |
| September 03, 2026 | 175.64M |
| September 02, 2026 | 170.92M |
| September 01, 2026 | 164.63M |
| August 31, 2026 | 169.35M |
| August 28, 2026 | 177.21M |
| August 27, 2026 | 187.43M |
| August 26, 2026 | 189.01M |
| August 25, 2026 | 198.44M |
| August 24, 2026 | 181.93M |
| August 21, 2026 | 178.79M |
| August 20, 2026 | 192.94M |
| August 19, 2026 | 217.31M |
| August 18, 2026 | 182.72M |
| August 17, 2026 | 186.65M |
| August 14, 2026 | 175.64M |
| Date | Value |
|---|---|
| August 13, 2026 | 185.08M |
| August 12, 2026 | 178.00M |
| August 11, 2026 | 170.92M |
| August 10, 2026 | 159.13M |
| August 07, 2026 | 173.28M |
| August 06, 2026 | 152.84M |
| August 05, 2026 | 144.98M |
| August 04, 2026 | 141.83M |
| August 03, 2026 | 125.32M |
| July 31, 2026 | 119.82M |
| July 30, 2026 | 137.12M |
| July 29, 2026 | 133.97M |
| July 28, 2026 | 140.26M |
| July 27, 2026 | 146.55M |
| July 24, 2026 | 161.49M |
| July 23, 2026 | 165.42M |
| July 22, 2026 | 178.00M |
| July 21, 2026 | 161.49M |
| July 20, 2026 | 152.84M |
| July 17, 2026 | 163.85M |
| July 16, 2026 | 153.63M |
| July 15, 2026 | 167.78M |
| July 14, 2026 | 158.34M |
| July 13, 2026 | 160.31M |
| July 10, 2026 | 174.07M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 9.157B |
| Oncolytics Biotech, Inc. | 92.30M |
| Sangamo Therapeutics, Inc. | 51.77M |
| Sarepta Therapeutics, Inc. | 2.381B |
| Anixa Biosciences, Inc. | 80.84M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -25.87M |
| Total Expenses (Quarterly) | 25.87M |
| EPS Diluted (Quarterly) | -0.3021 |
| Earnings Yield | -28.44% |
| Normalized Earnings Yield | -28.44 |